However, in spite of a recent study suggesting that more than a half of 364 ACC tumors may show actionable mutations based on OncoKB [10], clinical studies testing drugs that target the vascular endothelial growth factor (VEGF) pathway [11], the epidermal growth factor receptor (EGFR) pathway [12,13], the insulin-like growth factor 1 receptor (IGF-IR) pathway [14] or the mammalian target of rapamycin (mTOR) pathway [15,16] were discouraging so far [17,18,19,20]. The gene discussed is MTOR; the disease is adrenal cortex carcinoma.